30

Zhejiang Tailin Bioengineering Co Ltd

300813 · SHE · Healthcare / Medical Devices

18.93CNY-0.44 (-2.27%)

Price History

Full chart

Market Stats

Previous Close19.37
Open19.36
Day Range18.83 – 19.50
52-Week Range16.31 – 36.65
Volume1.10M
Market Cap2.77B
P/E (TTM)114.15
Forward P/E0.00
EPS0.20
Dividend Yield0.57%
Beta1.16
50-Day Avg20.38
200-Day Avg23.51

About

Zhejiang Tailin BioEngineering Co.,Ltd engages in the research and development, production, and sale of microbial detection, contamination control, process analysis, and inhibition protection in the life sciences field in China and internationally. The company primarily offers aseptic production and contamination control equipment, microbial testing products, and organic matter analysis technology products. It also provides pharma processing, such as pharma isolators, high-precision filling and dispensing, sterile transfer; cell and gene therapy; radiopharma; laboratory animal; leak test systems; biodecontamination, including VH2O2 sterilization system and dry fogging system; sterilization monitoring and validation; microbiological testing, comprising sterility and microbial limit test system and pretreatment instruments; and water quality, consisting of microbial monitoring and aquatic organism detection system, total organic carbon (TOC) analysis, enzyme substrate method, and automatic detection system for cryptosporidium and giardia. In addition, the company offers filtration membranes, such as flat and blotting membranes, IVD series, membrane filters and dispensers; and analytical instruments, including filter integrity testing, container closure integrity testers (CCIT), water activity meters, and biodegradation analysis systems. Its products are used in biopharmaceuticals, medical and health care, laboratory animal research, food safety, disease control, water quality monitoring, and environmental protection. The company was formerly known as Hangzhou Tailin Biotechnology Equipment Co., Ltd. and changed its name to Zhejiang Tailin BioEngineering Co.,Ltd in April 2015. Zhejiang Tailin BioEngineering Co.,Ltd was founded in 1993 and is based in Hangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Da Lin Ye
  • Employees790
  • HeadquartersNo. 2930, South Ring Road, Hangzhou, China, 310052, China
  • Websitehttps://www.tailingood.com

Leadership

  • Mr. Da Lin YeGM & Chairman · b. 1960
  • Mr. Xing Yue YeCFO & Secretary of the Board · b. 1974
  • Mr. Zhi Lin ShenDeputy GM & Director · b. 1971
  • Mr. Xin Qun XiaDeputy GM & Director · b. 1967
  • Wen Qin ZhouAccounting Supervisor
  • Mr. Xiaolu NiGeneral Manager of Tailin Life Sciences Division & Director · b. 1991

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue94.46M59.50M82.33M111.76M142.02M159.10M180.93M200.24M283.25M373.88M269.86M349.00M334.41M
Growth (%)--37.01%+38.37%+35.74%+27.07%+12.03%+13.72%+10.67%+41.46%+32.00%-27.82%+29.33%-4.18%
Cost of Revenue38.32M23.56M33.09M46.97M57.88M65.48M79.31M77.04M111.82M180.31M142.00M197.86M194.28M
Gross Profit56.15M35.94M49.24M64.79M84.14M93.61M101.61M123.20M171.43M193.57M127.86M151.14M140.13M
Gross Margin59.44%60.40%59.81%57.98%59.24%58.84%56.16%61.52%60.52%51.77%47.38%43.31%41.90%
Operating Expense34.07M28.93M36.69M37.85M37.26M39.99M63.30M71.27M101.64M113.96M106.08M138.74M139.29M
Operating Income22.08M7.01M12.56M26.94M46.88M53.62M38.31M51.93M69.79M79.61M21.78M12.40M844.80K
Operating Margin23.37%11.78%15.25%24.10%33.01%33.70%21.18%25.93%24.64%21.29%8.07%3.55%0.25%
EBITDA25.12M13.08M19.92M35.74M54.43M56.52M46.20M60.08M76.42M89.93M33.79M44.15M21.37M
EBITDA Margin26.59%21.98%24.20%31.98%38.33%35.52%25.54%30.00%26.98%24.05%12.52%12.65%6.39%
Net Income21.46M10.12M15.37M29.02M44.99M48.21M34.41M48.39M63.53M79.69M19.67M13.05M16.49M
Net Income Margin22.71%17.01%18.67%25.96%31.68%30.31%19.02%24.16%22.43%21.31%7.29%3.74%4.93%
R&D11.04M10.31M9.79M13.54M15.52M21.15M29.31M37.72M55.05M64.47M58.40M62.34M53.19M
R&D as % of Total Revenue11.69%17.33%11.89%12.12%10.93%13.29%16.20%18.84%19.43%17.24%21.64%17.86%15.91%
Interest Expense12.28K492.816.46K21.81K22.33K33.66K82.89K38.30K132.19K881.70K620.63K15.02M76.55K
Interest Expense % of Total Revenue0.01%0.00%0.02%0.02%0.02%0.02%0.05%0.02%0.05%0.24%0.23%4.30%0.02%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets81.97M78.39M131.22M155.97M193.59M255.12M266.91M539.99M655.87M922.66M973.51M959.91M959.34M
Total Liabilities17.06M23.35M33.79M39.66M47.10M60.42M37.81M95.75M158.49M275.21M323.27M139.18M155.04M
Total Equity64.92M55.04M97.42M116.31M146.48M194.70M229.11M444.24M497.38M647.45M648.76M820.05M804.29M
Cash14.90M7.95M21.01M65.98M66.96M44.40M51.95M322.15M302.46M577.15M396.98M264.87M149.09M
Total Debt---137.40K19.50M2.28M-3.75M12.88M145.47M157.59M3.67M-
Net Debt-14.90M-7.95M-21.01M-65.84M-47.46M-42.12M-51.95M-318.40M-289.59M-431.69M-239.39M-261.20M-149.09M

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow11.51M17.51M24.54M31.56M23.04M37.33M29.04M106.28M35.96M89.39M1.93M24.66M57.11M
Investing Cash Flow-2.31M-12.71M-27.63M23.82M-46.20M-45.94M-31.88M32.31M-169.37M-164.37M-172.34M-42.38M-6.98M
Financing Cash Flow--12.00M15.94M-10.13M-15.85M521.85K165.83M165.83M-13.73M183.85M-13.58M-10.46M-40.72M
Capital Expenditure2.31M1.07M2.22M14.24M26.54M42.29M22.37M7.07M25.91M29.14M176.24M18.54M46.89M
Free Cash Flow9.21M16.44M22.32M17.32M-3.50M-4.97M6.67M99.21M10.05M60.24M-174.31M6.12M10.22M
Dividends Paid-12.00M8.00M10.13M15.28M44.26K31.18M31.18M9.77M17.84M27.17M10.99M24.24M
FCF to OCF79.97%93.90%90.95%54.87%-15.18%-13.31%22.96%93.35%27.95%67.40%-9022.78%24.82%17.90%
Dividend Paid to FCF-72.99%35.84%58.50%-436.73%-0.89%467.67%31.43%97.22%29.61%-15.59%179.66%237.17%

Earnings

Report DateMar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 11, 2024May 14, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024May 14, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------
EPS Actual0.070.100.130.150.090.170.140.200.130.150.130.280.150.05-0.02-0.020.050.010.040.010.030.080.010.010.040.13
Surprise--------------------------
Timing---------------After-hoursAfter-hours---After-hours-----

Key Statistics & Ratios

Market Cap2.77B
Enterprise Value2.55B
Trailing P/E114.15
Forward P/E0.00
Price / Sales7.71
Price / Book3.56
EPS0.20
Book Value6.59
Revenue (TTM)359.10M
Gross Profit (TTM)154.83M
EBITDA29.97M
Profit Margin6.49%
Operating Margin13.49%
Return on Equity2.91%
Return on Assets0.92%
Shares Outstanding121.20M
Shares Float45.56M
Beta1.16
Dividend Yield0.57%
Dividend Rate0.13
Payout Ratio67.15%

Dividends

20261×
0.03May 6, 2026
20252×
0.10Sep 25, 20250.10May 28, 2025
20241×
0.10May 27, 2024
20231×
0.30May 11, 2023
20221×
0.23May 18, 2022
20211×
0.10May 26, 2021
20201×
0.29May 27, 2020

Stock Splits

  • May 11, 20231.3:1
  • May 18, 20221.6:1